A camelid ubiquibody–based tool for the clearance of pathogenic CRX

Most frameshift mutations that disrupt the activity of the transcription factor CRX exert a dominant-negative effect and are associated with elevated mRNA and protein levels. Here, we identified a subset of mutations that increase protein abundance without altering transcript levels, likely due to the loss of endogenous degradation signals and/or higher protein stability. We further demonstrate that CRX can be post-translationally regulated by ubiquitination, which controls its protein abundance via the proteasome. Based on this mechanism, we developed camelid ubiquibodies targeting novel CRX epitopes generated by frameshift variants to promote selective protein degradation. Notably, approximately two-thirds of pathogenic CRX variants are frameshift mutations, and several share common C-terminal epitopes, enabling a single targeting approach. As a proof-of-concept, we used the truncated protein encoded by the p.G122Afs*65 pathogenic variant to screen CRX-specific nanobodies and engineer them into ubiquibodies. We show that these mutant CRX proteins can be degraded more effectively than wild type by at least three different ubiquibodies via the proteasome. Together, these results establish protein degradation as a promising approach to eliminate frameshift-derived neoepitopes in dominant inherited retinal dystrophies and potentially other genetic disorders. In addition, this work provides new insights into the physiological regulation of CRX and contributes to a better understanding of the pathogenic mechanisms underlying its variants and associated clinical phenotypes.

Authors

Institutions

Publication Details

Journal
Cell Communication and Signaling
Published
2026-11-18
DOI
https://doi.org/10.1186/s12964-026-03340-x
Primary Topic
Retinal Development and Disorders
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A camelid ubiquibody–based tool for the clearance of pathogenic CRX

Rafael P. Vázquez‐Manrique, Federico Vicente Pallardó, C. Aguado, J.M. Millán et al.
1 links
Cell Communication and Signaling
Retinal Development and Disorders
article

A camelid ubiquibody–based tool for the clearance of pathogenic CRX

Rafael P. Vázquez‐Manrique, Federico Vicente Pallardó, C. Aguado, J.M. Millán, N. Galindo-Riera, E. Aller, V. Toulis, G. García-García, A. P. Gómez-Escribano, M. Botey, E. Rodríguez-Marsá, J. L. Sánchez-López, M. Esquerdo-Barragán, G. Marfany
article en

Abstract

Most frameshift mutations that disrupt the activity of the transcription factor CRX exert a dominant-negative effect and are associated with elevated mRNA and protein levels. Here, we identified a subset of mutations that increase protein abundance without altering transcript levels, likely due to the loss of endogenous degradation signals and/or higher protein stability. We further demonstrate that CRX can be post-translationally regulated by ubiquitination, which controls its protein abundance via the proteasome. Based on this mechanism, we developed camelid ubiquibodies targeting novel CRX epitopes generated by frameshift variants to promote selective protein degradation. Notably, approximately two-thirds of pathogenic CRX variants are frameshift mutations, and several share common C-terminal epitopes, enabling a single targeting approach. As a proof-of-concept, we used the truncated protein encoded by the p.G122Afs*65 pathogenic variant to screen CRX-specific nanobodies and engineer them into ubiquibodies. We show that these mutant CRX proteins can be degraded more effectively than wild type by at least three different ubiquibodies via the proteasome. Together, these results establish protein degradation as a promising approach to eliminate frameshift-derived neoepitopes in dominant inherited retinal dystrophies and potentially other genetic disorders. In addition, this work provides new insights into the physiological regulation of CRX and contributes to a better understanding of the pathogenic mechanisms underlying its variants and associated clinical phenotypes.

Cell Communication and Signaling
Universitat de València (ES), Hospital Universitari i Politècnic La Fe (ES), Centre for Biomedical Network Research on Rare Diseases (ES), Leitat Technological Center (ES), Instituto de Investigación Sanitaria La Fe (ES), Universitat de Barcelona (ES)
Generalitat Valenciana, Instituto de Salud Carlos III
Good health and well-being
Retinal Development and Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon